Tempest Therapeutics (NASDAQ:TPST) Stock Rating Reaffirmed by HC Wainwright

Tempest Therapeutics (NASDAQ:TPST)‘s stock had its “buy” rating reiterated by HC Wainwright in a research note issued to investors on Thursday, Benzinga reports. They presently have a $47.00 price objective on the stock.

Separately, Piper Sandler reissued an “overweight” rating and issued a $8.00 price target on shares of Tempest Therapeutics in a research report on Friday, June 21st. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, Tempest Therapeutics currently has an average rating of “Buy” and a consensus price target of $20.75.

Tempest Therapeutics Stock Down 19.3 %

Shares of TPST stock traded down $0.26 on Thursday, reaching $1.09. 49,030,629 shares of the company were exchanged, compared to its average volume of 1,678,846. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.17 and a quick ratio of 2.17. The company has a 50-day moving average of $1.36 and a 200-day moving average of $2.44. The company has a market cap of $24.21 million, a price-to-earnings ratio of -0.63 and a beta of -1.86. Tempest Therapeutics has a one year low of $0.92 and a one year high of $9.77.

Tempest Therapeutics (NASDAQ:TPST) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.42) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.05. Analysts anticipate that Tempest Therapeutics will post -1.43 earnings per share for the current year.

Insiders Place Their Bets

In other news, major shareholder Versant Venture Capital Vi, L. sold 387,999 shares of the firm’s stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $1.10, for a total value of $426,798.90. Following the transaction, the insider now owns 209,941 shares in the company, valued at $230,935.10. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 3.27% of the company’s stock.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Tempest Therapeutics stock. Dimensional Fund Advisors LP purchased a new position in shares of Tempest Therapeutics, Inc. (NASDAQ:TPST) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 25,084 shares of the company’s stock, valued at approximately $55,000. Dimensional Fund Advisors LP owned 0.11% of Tempest Therapeutics at the end of the most recent quarter. 22.52% of the stock is currently owned by hedge funds and other institutional investors.

Tempest Therapeutics Company Profile

Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.